Estrogen Receptor (ER) by Immunohistochemistry

Also known as: ER IHC

Clinical Use

Use

The Estrogen Receptor (ER) by Immunohistochemistry test is designed to evaluate the presence of estrogen receptors in breast cancer tissue samples. It aids in the determination of hormone receptor status, allowing for the assessment of whether a patient's cancer may respond to hormone therapies such as tamoxifen. Determining ER status is crucial for treatment planning in patients with breast cancer, as it helps guide therapeutic decisions to improve outcomes. This test is primarily used for breast cancer cases, but it can also be relevant in other malignancies where estrogen receptor status is a factor.

Special Instructions

Not provided.

Limitations

This test cannot be used to assess estrogen receptor status in non-representative, depleted, or decalcified tissue samples. Due to the nature of immunohistochemistry, results should be interpreted in the context of histopathological features and other clinical data. The test is performed as a technical service only, and it is critical to ensure appropriate specimen handling and preparation to avoid compromised results. It has not been cleared or approved by the FDA, and any use of the results should consider CLIA guidelines and other regulatory standards.

Test Details

New York Approved

Methodology

Immunoassay (IHC)

Biomarkers

Estrogen Receptor

Protein

IHC

Expression • Ordinal Score (e.g., TPS, CPS, H-score)

Result Turnaround Time

1-3 days

Specimen

Tissue (FFPE)

Volume

Not provided

Minimum Volume

2 slides

Container

Tissue transport kit

Collection Instructions

Formalin fix (10 percent neutral buffered formalin) and paraffin embed specimen (cells must be prepared into a cellblock). Protect paraffin block and/or slides from excessive heat. Transport tissue block or 5 unstained (3- to 5-micron thick sections), positively charged slides in a tissue transport kit. Available online through eSupply using ARUP Connect or contact ARUP Client Services.